Multiple myeloma (MM) updates in the relapsed/refractory setting at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, focused on optimizing the use of carilzomib, in addition to improving the treatment of lenalidomide refractory patients. Speaking from the meeting, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses these updates, including the ARROW trial (NCT02412878) of once vs. twice weekly carfilzomib, and the MMY1001 study (NCT01998971) of carfilzomib plus daratumumab. The OPTIMISMM trial (NCT01734928), which evaluated the efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone, is also explored.
Trial updates in R/R MM from ASCO: ARROW, MMY1001 & OPTIMISMM
